Centhaquine

Summary

Centhaquine (CHEMBL4594437) is a phase-3 clinical-stage small molecule (ATC C01CA28); indicated across 2 conditions including cardiovascular disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: C01CA28
• Indications: 2 conditions
• Clinical trials: 6
• Chemistry: 331.5 Da · C22H25N3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4594437
Name	Centhaquine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	162163
ATC	C01CA28
Molecular formula	C22H25N3
Molecular weight	331.5
InChIKey	UJNWGFBJUHIJKK-UHFFFAOYSA-N

SMILES: CC1=CC(=CC=C1)N2CCN(CC2)CCC3=NC4=CC=CC=C4C=C3

IUPAC name: 2-[2-[4-(3-methylphenyl)piperazin-1-yl]ethyl]quinoline

Also known as: Centhaquina, Centhaquine, COMPOUND-7173, PMZ-2010, PMZ2010, CENTHAQUINE

Parent form; salt/anhydrous children: CHEMBL4650227

Patent coverage: 13 distinct patent families (28 SureChEMBL compound mentions), from 3 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cardiovascular disorder	3	MONDO:0004995	EFO:0000319

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2	2
PHASE4	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05956418	PHASE4	RECRUITING	A Study to Assess the Safety and Efficacy of Centhaquine in Hypovolemic Shock Patients
NCT05251181	PHASE3	NOT_YET_RECRUITING	A Study to Assess Safety and Efficacy of Centhaquine as a Resuscitative Agent
NCT04045327	PHASE3	COMPLETED	Efficacy of PMZ-2010 (Centhaquine) a Resuscitative Agent for Hypovolemic Shock
NCT05241067	PHASE2	NOT_YET_RECRUITING	Multicentric, Randomized Study to Assess Safety and Efficacy of Centhaquine in Patients With ARDS
NCT04056065	PHASE2	COMPLETED	PMZ-2010 (Centhaquine) as a Resuscitative Agent for Hypovolemic Shock
NCT02408731	PHASE1	COMPLETED	A Study to Determine the Safety, Tolerability and Pharmacokinetics of PMZ-2010 (Centhaquin) in Healthy Volunteers

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).